Aptose Biosciences Inc. Files 8-K Report
Ticker: APTOF · Form: 8-K · Filed: Feb 20, 2025 · CIK: 882361
Sentiment: neutral
Topics: disclosure, financials, regulation-fd
Related Tickers: APTO
TL;DR
APTO filed an 8-K on Feb 20, 2025, covering Reg FD and financials. Nothing major revealed yet.
AI Summary
On February 20, 2025, Aptose Biosciences Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc., is incorporated in Canada and operates in the Biological Products sector.
Why It Matters
This 8-K filing provides important updates and disclosures regarding Aptose Biosciences Inc.'s regulatory compliance and financial reporting, which are crucial for investors to assess the company's status.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of information and does not appear to contain any immediate negative news or significant changes.
Key Numbers
- 001-32001 — SEC File Number (Identifies the company's filing with the SEC)
- 98-1136802 — IRS Number (Company's tax identification number)
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- Lorus Therapeutics Inc. (company) — Former company name
- Imutec Pharma Inc (company) — Former company name
- February 20, 2025 (date) — Date of earliest event reported
FAQ
What specific information is being disclosed under Regulation FD?
The filing indicates a Regulation FD Disclosure, but the specific details of the disclosure are not provided in the header information.
What types of financial statements and exhibits are included in this filing?
The filing lists 'Financial Statements and Exhibits' as an item of information, but the specific contents are not detailed in the provided text.
When was Aptose Biosciences Inc. formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc.?
The company was formerly known as Lorus Therapeutics Inc. with a name change date of 20140905, and prior to that, Imutec Pharma Inc. with a name change date of 19970113.
What is the primary business of Aptose Biosciences Inc. according to the SIC code?
The Standard Industrial Classification (SIC) code is 2836, which corresponds to 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)'.
Where is Aptose Biosciences Inc. headquartered?
The company's business and mailing address is located at 66 Wellington Street West, Suite 5300, TD Bank Tower Box 48, Toronto, A6, M5K 1E6.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 20, 2025 regarding Aptose Biosciences Inc. (APTOF).